Diagnosis of Alzheimers Disease
Tests to Assess Dementia
Neurological exam—examines the nervous system for evidence of other neurological disorders. This may include mental status testing of:
- Sense of time and place
- Problem-solving abilities
- Attention span
- Language skills
- Visual-spatial perception
- Learning capacity
- Decision-making skills
- Psychological evaluation—looks for depression or other emotional illnesses that may be the first sign of Alzheimers disease
- MRI scan , CT scan , and/or PET/CT scan —take detailed pictures of your brain to identify any abnormalities
- Lumbar puncture —tests the fluid surrounding the brain and spinal cord to look for infections that can cause dementia, or show markers of Alzheimers, such as beta amyloid and tau proteins
Blood and Urine Tests
- Probable Alzheimers disease—This indicates that other dementia-related disorders have likely been ruled out. The symptoms are most likely due to Alzheimers disease. At least two areas of cognition are affected. One area is a worsening of memory.
- Possible Alzheimers disease—The dementia is possibly caused by Alzheimers disease. There may be other disorders that are causing the dementia.
- Definite Alzheimers disease—This diagnosis can only be made at the time of death. It is done through an autopsy when the brain tissue can be examined. This is the only way to diagnose the disease with complete certainty.
Alzheimers disease. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed.ebscohost.com/about/about-us. Updated August 19, 2013. Accessed September 5, 2013.
Alzheimer's disease medications fact sheet. National Institute on Aging website. Available at: http://www.nia.nih.gov/Alzheimers/Publications/medicationsfs.htm. Updated July 2010. Accessed September 5, 2013.
Bombois S, Duhamel A, et al. A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer’s diagnosis. Curr Alzheimer Res. 2013;10(4):357-64.
Frisoni GB, Bocchetta M, et al. Imaging markers for Alzheimer disease: Which vs how. Neurology. 2013;81(5):487-500.
Ghidoni R, Benussi L, et al. Cerebrospinal fluid biomarkers in Alzheimer’s disease: the present and the future. Neurodegen Dis. 2011;8:413-420.
Hampel H, Frank R, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560-574.
Riverol M, Lopez OL. Biomarkers in Alzheimer’s disease. Front Neurol. 2011;2:46.
What is Alzheimer's? Alzheimer’s Association website. Available at: http://www.alz.org/alzheimers%5Fdisease%5Fwhat%5Fis%5Falzheimers.asp. Accessed September 5, 2013.
9/3/2014 DynaMed's Systematic Literature Surveillance. Available at: http://www.ebscohost.com/dynamed: Wippold FJ, Cornelius RS, et al. American College of Radiology (ACR) Appropriateness Criteria for dementia and movement disorders. Available at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/DementiaAndMovementDisorders.pdf. Updated 2014. Accessed September 3, 2014.
- Reviewer: Rimas Lukas, MD
- Review Date: 09/2014 -
- Update Date: 09/17/2014 -
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
Copyright © EBSCO Publishing
All rights reserved.